Product Details
Alternative Name: | OX40, TNFRSF 4 |
|
MW: | ~72kDa (SDS-PAGE). |
|
Source: | Produced in HEK 293 cells. The cysteine-rich region of human CD134 (OX40) (aa 29-214) is fused to the Fc portion of human IgG1. |
|
UniProt ID: | P43489 |
|
Concentration: | 1mg/ml after reconstitution. |
|
Formulation: | Lyophilized. Contains PBS. |
|
Purity: | ≥95% (SDS-PAGE) |
|
Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Bio Whittaker). |
|
Species reactivity: | Human, Mouse
|
|
Specificity: | Binds human and mouse CD134L (OX40L). |
|
Applications: | ELISA
|
|
Application Notes: | ELISA: binds to CD134L). Can be used together with anti-human IgG1 PAb to detect membrane-bound human CD134L. Has been used to ameliorate graft-versus-host disease, experimental allergic encephalomyelitis and inflammatory bowel disease. |
|
Reconstitution: | Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
|
Shipping: | Shipped on Blue Ice |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
|
Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
|
Scientific Background: | The CD134 receptor (OX40) is a member of the tumor necrosis factor receptor (TNF-R) family. CD134 is a type I transmembrane receptor. It contains 3 extracellular cysteine-rich motifs. CD134 is mainly expressed in activated lymphocytes. After interaction with its ligand CD134L (OX40L), CD134 interacts with TNF receptor-associated factor 2 (TRAF2), TRAF5 and mediate activation of nuclear factors NF-κB and AP1. CD134-CD134L have been reported to be involved in T cell selection, migration and induction of Th1 and Th2 cytokine pattern. Moreover, it is involved in anti-tumor immunity, cell adhesion and various auto-immune diseases. Historical data has shown that CD134 receptor blocks T cell proliferation induced by CD134L. |
|
Regulatory Status: | RUO - Research Use Only |
|
Figure: Receptor binding assay. Dose-dependent binding of recombinant human soluble CD134L to recobinant human CD134:Fc. Recombinant human CD134L saturates its receptor at a concentration range of 500-1’000ng/ml.
Method: Receptor binding assay: A 96 well ELISA plate was coated over night with 50ng CD134 (human):Fc (human) (recombinant) (Prod. No.
ALX-522-022) per well. After a blocking step, the indicated concentrations of CD134L, Soluble (human) (recombinant) (FLAG
®) (Prod. No.
ALX-522-023) were added for 1 hour. After extensive washing, Enhancer for Ligands (Prod. No.
ALX-804-034) was added for 1 hour. Bound ligand was revealed by a rabbit anti-mouse IgG-HRP incubated for 1 hour. OPD was used as a substrate, absorbance was measured at 490nm in an ELISA reader."
Please mouse over
Product Literature References
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes: E. Biagi, et al.; Blood
105, 2436 (2005),
Abstract;
Related Products